Brunstein Claudio G, Petersdorf Effie W, DeFor Todd E, Noreen Harriet, Maurer David, MacMillan Margaret L, Ustun Celalettin, Verneris Michael R, Miller Jeffrey S, Blazar Bruce R, McGlave Philip B, Weisdorf Daniel J, Wagner John E
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Biol Blood Marrow Transplant. 2016 Mar;22(3):487-92. doi: 10.1016/j.bbmt.2015.09.025. Epub 2015 Sep 30.
The impact of allele-level HLA mismatch is uncertain in recipients of double umbilical cord blood (UCB) transplantation. We report a single-center retrospective study of the clinical effect of using allele-level HLA mismatch HLA-A, -B, -C, -DRB1, and -DQB1 of the 2 UCB units. We studied 342 patients with hematologic malignancy. Donor-recipient pairs were grouped according to the number of matched HLA alleles, with 32 matched at 9-10/10, 202 at 6-8/10, and 108 at 2-5/10 alleles. The incidence of hematopoietic recovery, acute and chronic graft-versus-host disease, and nonrelapse mortality and treatment failure was similar between groups. In an exploratory analysis of 174 patients with acute leukemia, after adjusting for length of first remission and cytogenetic risk group, a 2-5/10 HLA match was associated with lower risk of relapse and treatment failure. These data indicate that a high degree of allele-level HLA mismatch does not adversely affect transplant outcomes and may be associated with reduced relapse risk in patients with acute leukemia.
在双份脐带血(UCB)移植受者中,等位基因水平的人类白细胞抗原(HLA)错配的影响尚不确定。我们报告了一项单中心回顾性研究,该研究探讨了使用两个UCB单位的等位基因水平HLA - A、-B、-C、-DRB1和-DQB1错配的临床效果。我们研究了342例血液系统恶性肿瘤患者。供受者对根据匹配的HLA等位基因数量进行分组,9 - 10/10个等位基因匹配的有32对,6 - 8/10个等位基因匹配的有202对,2 - 5/10个等位基因匹配的有108对。各组之间造血恢复、急性和慢性移植物抗宿主病以及非复发死亡率和治疗失败的发生率相似。在对174例急性白血病患者进行的探索性分析中,在调整首次缓解期长度和细胞遗传学风险组后,2 - 5/10 HLA匹配与较低的复发和治疗失败风险相关。这些数据表明,高度的等位基因水平HLA错配不会对移植结果产生不利影响,并且可能与急性白血病患者复发风险降低有关。